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Abstract. Photoacoustic imaging (PA imaging or PAI) has
shown great promise in the detection and monitoring of
cancer. Although nanocarrier-based contrast agents
have been studied for use in PAI, small molecule contrast
agents are required due to their ease of preparation, cost-
effectiveness, and low toxicity. Here, we evaluated the
usefulness of a novel cyanine dye IC7-1-Bu as a PAI con-
trast agent without conjugated targeting moieties for in vivo
tumor imaging in a mice model. Basic PA characteristics of
IC7-1-Bu were compared with indocyanine green (ICG), a
Food and Drug Administration approved dye, in an aque-
ous solution. We evaluated the tumor accumulation profile
of IC7-1-Bu and ICG by in vivo fluorescence imaging. In
vivo PAI was then performed with a photoacoustic tomog-
raphy system 24 and 48 h after intravenous injection of
IC7-1-Bu into tumor bearing mice. IC7-1-Bu showed
about a 2.3-fold higher PA signal in aqueous solution com-
pared with that of ICG. Unlike ICG, IC7-1-Bu showed high
tumor fluorescence after intravenous injection. In vivo PAI
provided a tumor to background PA signal ratio of approx-
imately 2.5 after intravenous injection of IC7-1-Bu. These
results indicate that IC7-1-Bu is a promising PAI contrast
agent for cancer imaging without conjugation of targeting
moieties. © 2014 Society of Photo-Optical Instrumentation Engineers (SPIE)
[DOI: 10.1117/1.JBO.19.9.090501]
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Since cancer is one of the leading causes of death worldwide,1
noninvasive imaging methods for cancer diagnosis are highly
valuable. Among several molecular imaging methods, photo-
acoustic imaging (PA imaging or PAI) has shown great promise
in detecting and monitoring cancer since it enables real-time
noninvasive imaging of tissues of interest with high contrast
but at depths of up to 5 cm.2,3 PAI can detect not only endog-
enous biological molecules such as oxyheme and deoxyheme
for the assessment of blood flow and oxygen concentration
in cancer vasculature,4 but also exogenous contrast agents tar-
geted to a specific molecular marker of interest to evaluate func-
tional alterations in disease sites.5 Background signals in PAI
can be minimized by using PAI contrast agents that absorb pho-
tons at a wavelength of 700–1000 nm [near infrared (NIR)
region] in a similar way as that seen for optical imaging (OI)
with NIR fluorescence probes.6,7 Nanosize probes, including
iron oxide nanoparticles, carbon nanotubes, gold nanocages,
gold nanorods, and nanospheres, which are occasionally conju-
gated with monoclonal antibodies such as trastuzumab, have
been developed as PAI contrast agents8,9 in order to achieve
high probe accumulation into tumor tissues by the enhanced per-
meability and retention effect. High levels of probe accumula-
tion would be required for PAI because of the relatively low
intrinsic sensitivity of this technique compared to OI.3,10
Although these nanotechnology-based contrast agents have
shown their usefulness in PAI, some difficulties in preparation
as well as uniformity control, cost-effectiveness, and toxicity are
issues that remain to be addressed before these compounds can
be used in clinical applications. Considering the potential draw-
backs of nanoprobes, small molecule-based contrast agents that
could be synthesized through ordinary synthetic procedures
would be highly valuable for use in clinical PAI.
We recently developed a novel NIR fluorescence cyanine dye,
IC7-1-Bu [3-butyl-2-(2-{3-[2-(3-butyl-1,1-dimethyl-1,3-dihydro-
benz[e]indol-2-ylidene)-ethylidene]-2-chloro-cyclohex-1-enyl}-
vinyl)-1,1-dimethyl-1H-benz[e]indolium, λex ¼ 823 nm, λem ¼
845 nm, molecular weight ¼ 667, Fig. 1(a)], which showed
unique properties as an OI probe for cancer imaging.11 IC7-
1-Bu accumulated in tumors of living mice after intravenous
administration to levels that allowed tumor imaging with OI
techniques without conjugation of any tumor-targeting moieties
such as monoclonal antibodies or nanocarriers. Building on
these previous results, we focus here on the unique tumor-
targeting ability of IC7-1-Bu using serum albumin as a drug
delivery carrier,11 and evaluated the potential of IC7-1-Bu as
a PAI contrast agent in preclinical experiments using tumor
bearing mice. Overall, we obtained additional evidence to sup-
port the promising applications of IC7-1-Bu as a PAI contrast
agent for tumor imaging in preclinical settings.
IC7-1-Bu was synthesized in three steps from cyclohexanone
and 1,1,2-trimethyl-1H-benz[e]indole as previously reported
(the overall yield was 47%). The compound was confirmed by
NMR and mass spectrometry.11 At the beginning of the evalu-
ation, we measured the PA signal of IC7-1-Bu in vitro and com-
pared it with that of indocyanine green (ICG), a Food and Drug
Administration approved cyanine dye that has been recently
applied for PAI after conjugation with a targeting moiety.12
Specifically, PA signals of IC7-1-Bu and ICG were measured
in an aqueous buffer containing 5 g∕dL bovine serum albumin
with excitation wavelengths of 830 and 810 nm for IC7-1-Bu
and ICG, respectively. The wavelengths were selected based
on the absorption peaks of each dye. Measured PA signals
were then standardized by irradiated laser intensity. As seen
in Fig. 1(b), which illustrates the correlation of PA signals
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with the dye concentration in the cuvettes, IC7-1-Bu showed
higher PA signals than ICG. The slope of a fitted first-order
line with an intercept of zero was approximately 2.2-fold higher
for IC7-1-Bu than for ICG. As a next step in the in vitro evalu-
ation, we performed PAI of buffer solutions including the dyes
(2.5 or 10 μM) using an Endra Life Sciences Nexus 128 instru-
ment (Endra Inc., Ann Arbor, Michigan).13 The IC7-1-Bu con-
centration was set to 2.5 μM based on the assumed IC7-1-Bu
concentration that accumulated in tumor tissue after intravenous
administration as determined from in vivo experiments
described below. IC7-1-Bu also exhibited a brighter signal
with ROI analyses showing that IC7-1-Bu had about a 2.3-
fold higher PA signal than that of ICG.
Since these in vitro results suggested the potential of IC7-1-
Bu as a PAI contrast agent, we next performed in vivo PAI
experiments using IC7-1-Bu in tumor bearing mice. Animal
experiments were conducted in accordance with institutional
guidelines and were approved by the Kyoto University Animal
Care Committee. Female nude mice (BALB/c nu/nu 4 weeks
old), supplied by Japan SLC, Inc., Hamamatsu, Shizuoka,
Japan, were housed under a 12-h light/12-h dark cycle and
given free access to food (D10001) and water. HeLa cells
(2 × 106 cells in 100 μL of phosphate buffered saline, ATCC)
were subcutaneously inoculated into the right hind legs of
mice. Fourteen days after transplantation, mice were used for the
imaging study (the average tumor size was 98 17 mm3). In an
in vivo imaging experiment, the Endra Life Sciences Nexus 128
and Clairvivo OPT (Shimadzu Co., Kyoto, Japan)6,11 were used
for PAI and OI, respectively. The whole body OI of tumor bear-
ing mice (n ¼ 3 each) revealed strong fluorescence in tumors 24
and 48 h after injection of IC7-1-Bu (0.5 μmol∕kg) [Fig. 2(a)],
which is in agreement with our previous results.11 However, ICG
(0.5 μmol∕kg) showed a rapid clearance of fluorescence via the
liver to the intestine [Fig. 2(a)], as would be expected from the
reported short biological half-life of ICG.14 This result clearly
suggests that ICG could be used as a PAI contrast agent for
tumor detection only after the conjugation of targeting moieties
such as monoclonal antibodies. The tumor to background fluo-
rescence ratio, which was calculated by defining fluorescence in
the neck area as the background,6,11 was approximately 2.4 in
the mice that were administered IC7-1-Bu 24 or 48 hours earlier.
Meanwhile, we further performed in vivo PAI with IC7-1-Bu
(1.25 μmol∕kg) administered to tumor bearing mice (n ¼ 3)
with an excitation wavelength of 830 nm. We obtained PA
images of the tumor region and contralateral muscle region
due to the limited field of view of the Nexus 128 system.13
In vivo PAI also showed higher PA signals in tumors 24 and
48 h after intravenous injection of IC7-1-Bu as compared to
the preadministration images [Figs. 2(b) and 2(c)]. The tumor
to background PA signal ratio calculated by defining PA signals
around the contralateral site (left hind leg) as the background
Fig. 1 In vitro characterization of IC7-1-Bu as a PAI contrast agent
compared to indocyanine green (ICG). (a) The structure of IC7-1-
Bu. (b) In vitro PA signals of aqueous solutions including IC7-1-Bu
or ICG. Correlation between a dye concentration and a PA signal
is designated as a line with a zero intercept (solid and dashed
lines represent the correlation of PA signals with IC7-1-Bu and
ICG, respectively). (c) Representative in vitro PA images of solutions
including IC7-1-Bu or ICG. (d) In vitro PA signals calculated from PA
images shown in (c) using AMIDE analysis software.
Fig. 2 In vivo OI and PAI experiments. (a) In vivo OI of tumor bearing mice 3, 24, and 48 h after intra-
venous injection of IC7-1-Bu and ICG. (b), (c) In vivo PAI of tumor bearing mice before administration and
at 24 or 48 h after intravenous injection of IC7-1-Bu. Representative PA images of the tumor region
(b) and contralateral muscle region (c) are shown in the middle column with photographs and PAI merged
photographs in the left and right columns, respectively.
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was 1.0 0.1, 3.0 0.3, and 2.3 0.9 at 0, 24, and 48 h,
respectively, after intravenous injection of IC7-1-Bu. Finally,
we estimated the quantity of IC7-1-Bu accumulated in the
tumor 24 h after IC7-1-Bu injection to support the IC7-1-Bu
PA signals obtained in the in vivo study. To do this, we measured
the IC7-1-Bu fluorescence of tumor homogenates (n ¼ 3) with
Clairvivo OPT and calculated the IC7-1-Bu quantity using a
standard curve we prepared separately using known standards.
The estimate yielded an uptake rate of 10.0 0.3% injected
dose per gram tissue in tumor, indicating the high tumor target-
ing ability of IC7-1-Bu. Other tumor targeting probes such as a
HER2-targeting liposome and the HER2-targeting monoclonal
antibody, trastuzumab, showed about 8%15 and 20% injected
dose per gram tissue,16 respectively. Therefore, these results
strongly support the in vivo PAI results described above.
In conclusion, these results indicate that IC7-1-Bu is a prom-
ising PAI contrast agent for cancer imaging that does not require
conjugation of targeting moieties. Further in vivo experiments
using varied tumor models are warranted to characterize addi-
tional properties of this compound.
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